124 related articles for article (PubMed ID: 1912294)
1. Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite.
Subramanyam B; Woolf T; Castagnoli N
Chem Res Toxicol; 1991; 4(1):123-8. PubMed ID: 1912294
[TBL] [Abstract][Full Text] [Related]
2. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes.
Usuki E; Pearce R; Parkinson A; Castagnol N
Chem Res Toxicol; 1996 Jun; 9(4):800-6. PubMed ID: 8831826
[TBL] [Abstract][Full Text] [Related]
3. Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.
Kalgutkar AS; Nguyen HT
Drug Metab Dispos; 2004 Sep; 32(9):943-52. PubMed ID: 15319335
[TBL] [Abstract][Full Text] [Related]
4. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats.
Subramanyam B; Rollema H; Woolf T; Castagnoli N
Biochem Biophys Res Commun; 1990 Jan; 166(1):238-44. PubMed ID: 2302206
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-catalyzed bioactivation of cyclic tertiary amines to form potential neurotoxins.
Castagnoli N; Castagnoli KP; Van der Schyf CJ; Usuki E; Igarashi K; Steyn SJ; Riker RR
Pol J Pharmacol; 1999; 51(1):31-8. PubMed ID: 10389142
[TBL] [Abstract][Full Text] [Related]
6. Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+.
Wu E; Shinka T; Caldera-Munoz P; Yoshizumi H; Trevor A; Castagnoli N
Chem Res Toxicol; 1988; 1(3):186-94. PubMed ID: 2979730
[TBL] [Abstract][Full Text] [Related]
7. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.
Igarashi K; Kasuya F; Fukui M; Usuki E; Castagnoli N
Life Sci; 1995 Nov; 57(26):2439-46. PubMed ID: 8847965
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
9. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats.
Ablordeppey SY; Borne RF
Pharmacol Biochem Behav; 1993 Nov; 46(3):739-44. PubMed ID: 8278454
[TBL] [Abstract][Full Text] [Related]
10. Dehydration is the first step in the bioactivation of haloperidol to its pyridinium metabolite.
Fang J; Gorrod JW
Toxicol Lett; 1991 Dec; 59(1-3):117-23. PubMed ID: 1755019
[TBL] [Abstract][Full Text] [Related]
11. Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice.
Van der Schyf CJ; Castagnoli K; Usuki E; Fouda HG; Rimoldi JM; Castagnoli N
Chem Res Toxicol; 1994; 7(3):281-5. PubMed ID: 8075357
[TBL] [Abstract][Full Text] [Related]
12. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 1-methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells: role of monoamine oxidase A.
Basma AN; Heikkila RE; Nicklas WJ; Giovanni A; Geller HM
J Neurochem; 1990 Sep; 55(3):870-7. PubMed ID: 2384758
[TBL] [Abstract][Full Text] [Related]
13. Identification of potentially neurotoxic pyridinium metabolite in the urine of schizophrenic patients treated with haloperidol.
Subramanyam B; Pond SM; Eyles DW; Whiteford HA; Fouda HG; Castagnoli N
Biochem Biophys Res Commun; 1991 Dec; 181(2):573-8. PubMed ID: 1755839
[TBL] [Abstract][Full Text] [Related]
14. Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases.
Dalvie DK; O'Connell TN
Drug Metab Dispos; 2004 Jan; 32(1):49-57. PubMed ID: 14709620
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of the oxidation of a pyridinium metabolite of haloperidol by human placenta: the effect of smoking.
Fang J; Song J
J Pharm Pharm Sci; 2012; 15(4):538-47. PubMed ID: 23106957
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity study of the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. I. Evaluation of the biological activity of MPTP analogs.
Youngster SK; Sonsalla PK; Sieber BA; Heikkila RE
J Pharmacol Exp Ther; 1989 Jun; 249(3):820-8. PubMed ID: 2786564
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.
Kalgutkar AS; Taylor TJ; Venkatakrishnan K; Isin EM
Drug Metab Dispos; 2003 Mar; 31(3):243-9. PubMed ID: 12584149
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions.
Weissman J; Trevor A; Chiba K; Peterson LA; Caldera P; Castagnoli N; Baillie T
J Med Chem; 1985 Aug; 28(8):997-1001. PubMed ID: 3874963
[TBL] [Abstract][Full Text] [Related]
19. Comparative toxicity and antioxidant activity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B-generated metabolites in isolated hepatocytes and liver microsomes.
Ekström G; Di Monte D; Sandy MS; Smith MT
Arch Biochem Biophys; 1987 May; 255(1):14-8. PubMed ID: 3496045
[TBL] [Abstract][Full Text] [Related]
20. Interactions of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine with monoamine oxidases.
Singer TP; Salach JI; Castagnoli N; Trevor A
Biochem J; 1986 May; 235(3):785-9. PubMed ID: 3489461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
